NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Radionetics Oncology

Radionetics Oncology

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://radionetics.com/

Last Round

Strategic

Jul 1, 2024

Est. Valuation

$60.61M

Total Funding Raised

$222.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Radionetics Oncology is a biopharmaceutical company that discovers and develops novel small-molecule radiopharmaceuticals targeting G-protein coupled receptors for the treatment of solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

radiopharmaceuticalsradioligand therapytargeted cancer therapyoncologydrug discoverybiopharmaceuticalGPCRprecision medicinetheranosticsradiotherapysmall-molecule drugsclinical-stage biotechdrug licensingtarget validationbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Radionetics Oncology Comparables

Compare Radionetics Oncology with similar companies based on industry and business-model similarity.

Radionetics Oncology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Alpha-9 Oncology
90%
Abdera Therapeutics
89%
Ratio Therapeutics Inc.
85%

Radionetics Oncology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicJul 1, 2024
Series AJan 3, 2024
SeedOct 18, 2021

Key People

Founding team and executive leadership

Alyssa Levin

Chief Financial Officer

Executive Team

Brett Ewald

Chief Operating Officer

Executive Team

Radionetics Oncology Investors

Notable investors and investment history

Radionetics Oncology investors
InvestorRounds
Frazier Healthcare PartnersSeed
DCVC BioSeries A
GordonMD Global InvestmentsSeries A
5AM VenturesSeries A, Seed
Frazier Life SciencesSeries A
DCVC (Data Collective)Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 11, 2026

    Announced a strategic agreement with Eli Lilly.

  • Jan 3, 2024

    $53M round completed.

Radionetics Oncology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Radionetics Oncology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Radionetics Oncology's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range48
Year Founded2021
Last FundingJul 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.